References
- Zhang Y. The magic bullets and tuberculosis drug targets. Annu. Rev. Pharmacol. Toxicol. 45, 529–564 (2005).
- Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob. Agents Chemother. 46(2), 267–274 (2002).
- Nguyen L, Pieters J. Mycobacterial subversion of chemotherapeutic reagents and host defense tactics: challenges in tuberculosis drug development. Annu. Rev. Pharmacol. Toxicol. 49, 427–453 (2009).
- Udwadia ZF. MDR, XDR, TDR tuberculosis: ominous progression. Thorax 67(4), 286–288 (2012).
- Dorman SE, Chaisson RE. From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. Nat. Med. 13(3), 295–298 (2007).
- Bolten BM, DeGregorio T. From the analyst’s couch. Trends in development cycles. Nat. Rev. Drug Discov. 1(5), 335–336 (2002).
- Davies J. Afterword. Learning and teaching: a perspective reflection. In: Frontiers in Antimicrobial Resistance: A Tribute to Stuart B. Levy. White DG, Alekshun MN, Mcdermott PF (Eds). ASM Press, Washington, DC, USA 551–554 (2005).
- Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. The challenge of new drug discovery for tuberculosis. Nature 469(7331), 483–490 (2011).
- D’Costa VM, King CE, Kalan L et al. Antibiotic resistance is ancient. Nature 477(7365), 457–461 (2011).
- D’Costa VM, McGrann KM, Hughes DW, Wright GD. Sampling the antibiotic resistome. Science 311(5759), 374–377 (2006).
- Chikamatsu K, Mizuno K, Yamada H, Mitarai S. Crossresistance between rifampicin and rifabutin among multi-drug resistant Mycobacterium tuberculosis strains. Kekkaku 84(9), 631–633 (2009).
- Senol G, Erbaycu A, Ozsöz A. Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey. J. Chemother. 17(4), 380–384 (2005).
- Gordin FM. Rifapentine for the treatment of tuberculosis: is it all it can be? Am. J. Respir. Crit. Care Med. 169(11), 1176–1177 (2004).
- Sharma PC, Jain A, Jain S. Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects. Acta Pol. Pharm. 66(6), 587–604 (2009).
- Takiff H, Guerrero E. Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob. Agents Chemother. 55(12), 5421–5429 (2011).
- Wright GD. Resisting resistance: new chemical strategies for battling superbugs. Chem. Biol. 7(6), R127–R132 (2000).
- Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE 3rd, Blanchard JS. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323(5918), 1215–1218 (2009).
- Willand N, Dirié B, Carette X et al. Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat. Med. 15(5), 537–544 (2009).
- Weber W, Schoenmakers R, Keller B et al. A synthetic mammalian gene circuit reveals antituberculosis compounds. Proc. Natl Acad. Sci. USA 105(29), 9994–9998 (2008).
Website
- The First New Tuberculosis Drug in Decades: Promise and Challenges. www.treatmentactiongroup.org/tagline/2011/winter/new-tb-drug-decades